All Programs

Use the tool below to view all available Global Neurology Academy Series

Modern MS Management: Leveraging Technology to Support Brain Health
Modern MS Management: Leveraging Technology to Support Brain Health
Global Neurology Academy
Modern MS Management: Leveraging Technology to Support Brain Health
- Victoria Leavitt, PhD
- Gates B. Colbert, MD
Addressing Barriers to MenB and MenACWY Vaccination
Addressing Barriers to MenB and MenACWY Vaccination
Global Neurology Academy
Addressing Barriers to MenB and MenACWY Vaccination
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiers
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
- Marc Haut, PhD
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
CME/CE
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
1.00 credit
- Marwan Sabbagh, MD, FAAN
- Alireza Atri, MD, PhD
- Christoph U. Correll, MD
1.00 credit
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Global Neurology Academy
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
The Future of MS Management: Novel Agents and Clinical Approaches
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiers
The Future of MS Management: Novel Agents and Clinical Approaches
- Marisa McGinley, DO
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the MAPLE-MS Pharmacovigilance Program
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the MAPLE-MS Pharmacovigilance Program
NeuroFrontiers
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the MAPLE-MS Pharmacovigilance Program
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiers
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiers
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
- David Gate, PhD
Understanding MS: Managing Hidden and Overlooked Symptoms
Understanding MS: Managing Hidden and Overlooked Symptoms
Global Neurology Academy
Understanding MS: Managing Hidden and Overlooked Symptoms
- Marisa McGinley, DO
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiers
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiers
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
NeuroFrontiers
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
The Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
The Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
Global Neurology Academy
The Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
- Ryan Quigley
- Lyn R. Griffiths
Intermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
Intermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
NeuroFrontiers
Intermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
NeuroFrontiers
Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy

All Programs

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

All Programs

Popular

Title

Share on ReachMD